Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00313820
Recruitment Status : Completed
First Posted : April 12, 2006
Results First Posted : October 9, 2009
Last Update Posted : October 15, 2009
Sponsor:
Information provided by:
Pfizer

Brief Summary:
Efficacy and Safety of flexibly dosed pregabalin compared to placebo among subjects with central post stroke pain (CPSP)

Condition or disease Intervention/treatment Phase
Central Neuropathic Pain Drug: Pregabalin Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A 13-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150-600 Mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Central Post-Stroke Pain (CPSP)
Study Start Date : August 2006
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Pregabalin

Arm Intervention/treatment
Active Comparator: Pregabalin
The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
Drug: Pregabalin
Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.

Placebo Comparator: Placebo
The change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
Drug: Placebo
Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.




Primary Outcome Measures :
  1. Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS) [ Time Frame: Up to Week 12 ]

Secondary Outcome Measures :
  1. Pain Score as Measured by DPRS [ Time Frame: Week 1, Week 2, Week 3, Week 6, Week 9, and Week 12 ]
  2. Number of Subjects With at Least a 30% Reduction From Baseline in Mean Pain Score at Endpoint [ Time Frame: Baseline, Week 12 ]
  3. Number of Subjects With at Least a 50% Reduction From Baseline in Mean Pain Score at Endpoint [ Time Frame: Baseline, Week 12 ]
  4. Weekly Mean Sleep Interference Score From Daily Sleep Diary (Daily Sleep Interference Scale [DSIS]) [ Time Frame: Week 1, Week 2, Week 3, Week 6, Week 9, and Week 12 ]
  5. Short Form-McGill Pain Questionnaire (SF-MPQ Visual Analog Scale [VAS]) - Part B Only [ Time Frame: Week 12 ]
  6. Neuropathic Pain Symptom Inventory (NPSI) [ Time Frame: Week 12 ]
  7. Medical Outcome Study (MOS) Sleep Scale [ Time Frame: Week 12 ]
  8. Number of Subjects With Yes or No Response for Medical Outcome Study (MOS) Sleep Scale - Optimal Sleep [ Time Frame: Week 12 ]
  9. Hospital Anxiety and Depression Scale (HADS) - ITT Population [ Time Frame: Week 12 ]
  10. Euro Quality of Life (EQ-5D)- Health State Profile Utility Score [ Time Frame: Week 12 ]
  11. EQ-5D - VAS [ Time Frame: Week 12 ]
  12. Patient Global Impression of Change (PGIC) [ Time Frame: Week 12 ]
  13. Clinical Global Impression of Change (CGIC) [ Time Frame: Week 12 ]
  14. Quantitative Assessment of Neuropathic Pain (QANeP) - Sensory Threshold [ Time Frame: Baseline, Week 12 ]
  15. QANeP - Pain Rating Scales [ Time Frame: Baseline, Week 12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Positive history of clinical stroke at least 4 months prior to randomization CPSP--3 months prior to screening

Exclusion Criteria:

  • History of dementia or any other severe cognitive impairment
  • Diabetic Peripheral Neuropathy (DPN)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00313820


Locations
Layout table for location information
Australia, New South Wales
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia, 2010
Pfizer Investigational Site
East Gosford, New South Wales, Australia, 2250
Pfizer Investigational Site
St Leonards, New South Wales, Australia, 2065
Pfizer Investigational Site
Warrawong, New South Wales, Australia, 2502
Australia, Queensland
Pfizer Investigational Site
Herston, Queensland, Australia
Australia, Victoria
Pfizer Investigational Site
Footscray, Victoria, Australia, 3011
Australia, Western Australia
Pfizer Investigational Site
Perth, Western Australia, Australia, 6000
China
Pfizer Investigational Site
Beijing, China, 100083
Pfizer Investigational Site
Beijing, China, 100730
Pfizer Investigational Site
Guang Zhou, China, 510180
Pfizer Investigational Site
Shang Hai, China, 200003
Pfizer Investigational Site
Shang Hai, China, 200040
Hong Kong
Pfizer Investigational Site
New Territories, Hong Kong
India
Pfizer Investigational Site
Bangalore, India, 560 034
Pfizer Investigational Site
Bangalore, India, 560 054
Pfizer Investigational Site
Chennai, India, 600 010
Pfizer Investigational Site
Lucknow, India, 226 014
Pfizer Investigational Site
New Delhi, India, 110 002
Indonesia
Pfizer Investigational Site
Jakarta, Indonesia, 10430
Pfizer Investigational Site
Surabaya, Indonesia, 60286
Korea, Republic of
Pfizer Investigational Site
Seoul, Korea, Republic of, 138-736
Malaysia
Pfizer Investigational Site
Kuala Lumpur, Malaysia, 59100
Pfizer Investigational Site
Penang, Malaysia, 11600
Pfizer Investigational Site
Selangor, Malaysia, 68100
Pakistan
Pfizer Investigational Site
Karachi, Sindh, Pakistan
Pfizer Investigational Site
Karachi, Pakistan
Philippines
Pfizer Investigational Site
Manila, Philippines, 1000
Pfizer Investigational Site
Manila, Philippines, 1003
Taiwan
Pfizer Investigational Site
Gueishan Shiang, Taoyuan Hsien, Taiwan
Pfizer Investigational Site
Taichung, Taiwan, 407
Pfizer Investigational Site
Taipei, Taiwan, 112
Thailand
Pfizer Investigational Site
Ratchatewee, Bangkok, Thailand, 10400
Pfizer Investigational Site
Bangkok, Thailand, 10400
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Director, Clinical Trials Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00313820    
Other Study ID Numbers: A0081063
First Posted: April 12, 2006    Key Record Dates
Results First Posted: October 9, 2009
Last Update Posted: October 15, 2009
Last Verified: October 2009
Keywords provided by Pfizer:
Post-stroke pain, pregabalin
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuralgia
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Pain
Neurologic Manifestations
Signs and Symptoms
Pregabalin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs